Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Teva
AstraZeneca
Cantor Fitzgerald
Chubb
Federal Trade Commission
US Department of Justice
Cipla
Farmers Insurance

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,207,158

« Back to Dashboard

Summary for Patent: 8,207,158
Title:5HT2c receptor modulators
Abstract: The present invention relates to novel compounds of Formula (I): ##STR00001## which act as 5HT.sub.2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Inventor(s): Smith; Brian (San Diego, CA), Smith; Jeffrey (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/118,126
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,207,158

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY ➤ Try a Free Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY ➤ Try a Free Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN ➤ Try a Free Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY ➤ Try a Free Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,207,158

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,953,787 5HT2C receptor modulators ➤ Try a Free Trial
8,273,734 5HT.sub.2C receptor modulators ➤ Try a Free Trial
8,546,379 5HT.sub.2C receptor modulators ➤ Try a Free Trial
8,846,906 5HT.sub.2C receptor modulators ➤ Try a Free Trial
8,993,750 5HT.sub.2C receptor modulators ➤ Try a Free Trial
8,575,149 5HT2C receptor modulators ➤ Try a Free Trial
7,514,422 5HT.sub.2c receptor modulators ➤ Try a Free Trial
7,977,329 5HT.sub.2C receptor modulators ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,207,158

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 373464 ➤ Try a Free Trial
Poland 211314 ➤ Try a Free Trial
Poland 211333 ➤ Try a Free Trial
Ukraine 77788 ➤ Try a Free Trial
Poland 396873 ➤ Try a Free Trial
Portugal 1411881 ➤ Try a Free Trial
Poland 219017 ➤ Try a Free Trial
New Zealand 535381 ➤ Try a Free Trial
Norway 323528 ➤ Try a Free Trial
Norway 20044928 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
Baxter
Cerilliant
Dow
Farmers Insurance
Boehringer Ingelheim
Chubb
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot